ストックスクリーナーアプリを入手
3.52
6.88%
-0.26
アフターアワーズ：
3.41
-0.11
-3.12%
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Chart - ChartMill
Number of shareholders of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals (ZNTL) Consolidates Near Support as Biotech Sector Awaits CatalystsFloat Adjusted Cap - newsline.com
Zentalis Pharmaceuticals Insider Sellers Vindicated After 10% Drop - simplywall.st
ZNTL Should I Buy - Intellectia AI
ZNTL: Azenosertib shows promise in PROC, with strong efficacy and future combination plans underway - TradingView
Zentalis grants 191,000 stock options to new hires under Nasdaq inducement rule. - Pluang
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Expands Board, Appoints New Director - TipRanks
Zentalis strengthens commercial leadership with appointments of Shannon Campbell to board of directors and Sarah Kelly as SVP of commercial strategy - marketscreener.com
Zentalis adds board member, commercial executive ahead of trial data - Investing.com
Zentalis adds board member, commercial executive ahead of trial data By Investing.com - Investing.com Canada
Zentalis (ZNTL) director Shannon Campbell receives 114,200-share RSU award - Stock Titan
Zentalis Pharmaceuticals (ZNTL) expands board, awards RSUs to new director - Stock Titan
Zentalis (ZNTL) director Campbell Shannon files routine Form 3 insider report - Stock Titan
Zentalis Strengthens Commercial Leadership with - GlobeNewswire
Zentalis Pharmaceuticals (ZNTL) Rises 1.52% as Stock Tests Key ResistanceNAAIM Exposure - newsline.com
ZNTL: Azenosertib shows promising efficacy and safety in ovarian cancer, with pivotal data expected this year - TradingView
Zentalis Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Zendesk Inc (ZEN) - Minichart
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
ZNTL Q1 2026 Earnings: Pre-Revenue Biotech Posts Wider-than-Expected Net LossRetail Earnings Report - The Legal Advocate
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewswire
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Stock: Down -10.37%, Support Test at $3.45 2026-05-18Golden Cross - The Legal Advocate
What's behind the surge in Zentalis stock? - MSN
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus - AD HOC NEWS
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - Moomoo
Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO) - The Globe and Mail
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.5, Implies 52% Upside - TradingView
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts - TipRanks
Zentalis Pharmaceuticals 1Q Loss/Shr 50c >ZNTL - Moomoo
TradingKey - TradingKey
Is Zentalis Pharmaceuticals (ZNTL) Attractive After Q1 2026 Earn - GuruFocus
ZNTL Advances Key Trials for Ovarian Cancer Treatment - GuruFocus
ZNTL: Azenosertib shows >30% ORR in Cyclin E1-positive PROC, targeting a major unmet need - TradingView
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zentalis Advances Azenosertib with New Trial Updates - TipRanks
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - The Manila Times
Zentalis (ZNTL) trims Q1 loss as azenosertib moves into Phase 3 - Stock Titan
Zentalis Pharmaceuticals, Inc. 1Q 2026: Net income $(35.4)M, EPS $(0.50) — 10-Q Summary - TradingView
Zentalis (Nasdaq: ZNTL) trims Q1 2026 loss while pushing azenosertib toward pivotal ovarian cancer milestones - Stock Titan
Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com South Africa
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):